Rufomycin Targets ClpC1 Proteolysis in Mycobacterium tuberculosis and M. abscessus-Reference-Cited by-同舟云学术

Rufomycin Targets ClpC1 Proteolysis in Mycobacterium tuberculosis and M. abscessus

Published:2019-03 Issue:3 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Choules Mary P.¹²,Wolf Nina M.¹,Lee Hyun²³,Anderson Jeffrey R.¹,Grzelak Edyta M.¹,Wang Yuehong¹,Ma Rui¹,Gao Wei¹²,McAlpine James B.¹²,Jin Ying-Yu⁴,Cheng Jinhua⁵,Lee Hanki⁴,Suh Joo-Won⁴⁵,Duc Nguyen Minh⁴,Paik Seungwha⁶⁷,Choe Jin Ho⁶⁷,Jo Eun-Kyeong⁶⁷,Chang Chulhun L.⁸,Lee Jong Seok⁹,Jaki Birgit U.¹²,Pauli Guido F.¹²,Franzblau Scott G.¹,Cho Sanghyun¹

Affiliation:

1. Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA

2. Department of Medicinal Chemistry & Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA

3. Center for Biomolecular Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA

4. Center for Nutraceutical and Pharmaceutical Materials, Myongji University, Cheoin-gu, Gyeonggi-do, Republic of Korea

5. Division of Bioscience and Bioinformatics, College of Natural Science, Myongji University, Cheoin-gu, Gyeonggi-do, Republic of Korea

6. Department of Microbiology, Chungnam National University School of Medicine, Daejeon, Republic of Korea

7. Infection Control Convergence Research Center, Chungnam National University School of Medicine, Daejeon, Republic of Korea

8. Department of Laboratory Medicine, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea

9. International Tuberculosis Research Center, Changwon, Republic of Korea

Abstract

ClpC1 is an emerging new target for the treatment of Mycobacterium tuberculosis infections, and several cyclic peptides (ecumicin, cyclomarin A, and lassomycin) are known to act on this target. This study identified another group of peptides, the rufomycins (RUFs), as bactericidal to M. tuberculosis through the inhibition of ClpC1 and subsequent modulation of protein degradation of intracellular proteins.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Rural Development Administration

Ministry of Science, ICT and Future Planning

HHS | NIH | National Center for Complementary and Integrative Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02204-18

Reference56 articles.